Clinical Trials

India combines a massive, treatment‑naive patient population with skilled researchers and strong healthcare infrastructure. Enrollment is quick and costs are significantly lower compared to other countries.

 For emerging and established biopharma companies alike, speeding up trial schedules and reducing budget is essential to advancing therapies.

For specific therapeutic areas, the advantages are even stronger:

• Cardiovascular disease: India has one of the world’s largest populations of patients with heart conditions, enabling rapid recruitment for studies in hypertension, heart failure, and related indications.
• Diabetes: With over 100 million people living with diabetes, India offers unmatched access to diverse patient groups for both small‑molecule and biologic trials.
• Respiratory and lung disease: High incidence of asthma, COPD, and other respiratory conditions provides ample treatment‑naive populations for targeted studies.
• Vaccines: India is the largest global producer of vaccines by volume, supported by experienced CROs and CDMOs.
• Oncology, Endocrinology, Neurology and all other therapeutic areas: Due to the large population, there are high instances of all distinct patient pools in India.

Amritt helps you succeed in India. Knowing where to run your trial is only part of the solution – knowing how to run it is critical. That’s where we come in.

• We vet every CRO in our network, ensuring quality and compliance with the US Food and Drug Administration(FDA) and the European Medicines Association(EMA) regulatory standards.
• We match you with the right CROs based on your needs, study design, and timeline.
• We manage the relationship from start to finish, providing oversight, communication, and problem‑solving so you can focus on science and strategy rather than logistics.

Let us help you reduce costs, accelerate enrollment, and deliver results that stand up to global regulatory requirements.

Schedule a 30‑minute call with our team to explore how we can support your next clinical milestone.